Recently, potent incretin mimetics, including semaglutide (a GLP1 receptor agonist) and tirzepatide (a dual GLP1 and GIP receptor agonist), have become widely available for patients with obesity or who have overweight and have a cardiovascular risk factor
Xiong, N., Zhao, Y., Dong, X., Zheng, J., & Sun, Y
Clinical data shows tirzepatide produces greater average weight loss than semaglutide alone, with trials demonstrating up to 22.5% body weight reduction versus 18% for semaglutide
doi: 10.4088/JCP.14m09505 54 Paulose-RamRGraberJEWoodwellDAhluwaliaN
Start your intake Current GLP-1 Market Pricing and Supply Dynamics Brand-name semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) dominate the market but carry premium pricing due to patent protection and manufacturing complexity
How to choose the spot : Select a location below the ribs and at least 2 inches away from the navel to avoid scar tissue or sensitivity